Developer docs
API playgroundTry for free, no card

Search company profiles

Rubix Group

Full company profile

uuid003952n

Namestring
Rubix Group
Legal namestring
Rubix Group (HK) Limited
Websiteurl
rubixgp.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Rubix Group (HK) Limited is a Hong Kong-incorporated private single family office, established in 2020, that deploys proprietary family capital into healthcare and life sciences opportunities across Greater China. The firm serves exclusively the members of its controlling family and family-owned investment holding vehicles; it does not solicit, accept, or manage capital from third parties and does not charge management or performance fees. Its sole 'customer' is the family itself, and its revenue, in the economic sense, is derived from investment gains on the family's own portfolio rather than from fee income.

The firm invests across four healthcare verticals in Greater China: Biotech & Therapeutics (novel biologics, small molecules, cell and gene therapy, oncology, immunology, CNS, rare disease, biosimilars); Medical Devices & MedTech (surgical robotics, diagnostic imaging, interventional devices, orthopaedics, IVD, wearables); Healthcare Services & Infrastructure (CRO/CDMO, hospital groups, specialty clinics, pharmacy chains, healthcare IT, laboratory services); and Digital Health & AI (AI drug discovery, telemedicine, clinical decision support, genomics, precision medicine) as an emerging focus. Its core capabilities cover deal origination through local biotech networks, independent commercial and scientific due diligence, bespoke transaction structuring (direct equity, convertibles, structured notes, SPVs), active position stewardship with board representation, risk governance, and exit planning across HKEX, Shanghai, and Shenzhen exchanges.

There is no proprietary technology platform; the firm's edge is grounded in on-the-ground presence in Hong Kong, local-language diligence, and relationships with Greater China healthcare management teams. Operating infrastructure is distributed across Hong Kong (principal entity), Cayman Islands (Rubix Capital SPC), British Virgin Islands (Rubix Capital (BVI) Ltd, an Approved Manager), and Malaysia (operations centre), while investment decision-making remains independent at Rubix Group (HK) Limited, which is not licensed by the Securities and Futures Commission of Hong Kong. The family principal, Alexander Ariana, serves as CEO and oversees the principal investing programme.

Short descriptiontext

Rubix Group (HK) Limited is a Hong Kong-based private single family office that deploys proprietary family capital into Greater China healthcare and life sciences opportunities across biotech, medical devices, digital health, and healthcare services verticals, serving exclusively its controlling family group.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersHong Kong, Hong Kong SAR China
HQ citystring
Hong Kong
HQ countrystring
Hong Kong SAR China
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
family office investing, healthcare venture capital, life sciences investment, principal investing services, private equity healthcare
Industry1 code
PRIMARYFSAAADAH
Family Office Investment Platforms & Direct Investing (PE/VC/Co-Invest)
Financial & Insurance/Asset & Wealth Management/Family Offices (Single- & Multi-Family)
NAICS code1 code
  • Portfolio Management and Investment Advice523940
SIC code1 code
  • Investors, Nec6799
Product category
Family Office Healthcare Investment
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Investment Returns on Proprietary Family Capital
TypeOne Time License
Description

Rubix Group generates returns through investment gains on the family's proprietary capital deployed across Greater China healthcare and life sciences opportunities. As a single family office, it does not charge management fees or performance fees to external clients. Revenue is derived entirely from appreciation and returns on the family's own investment portfolio.

rubixgp.com
Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Rubix Group is a Hong Kong-incorporated private single family office that deploys its controlling family's proprietary capital directly into Greater China healthcare and life sciences companies. The firm concentrates on four verticals — biotech and therapeutics, medical devices and MedTech, digital health and AI, and healthcare services and infrastructure — sourcing proprietary deal flow through local networks and managing direct equity, convertible, and structured positions as principal investor.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Rubix Group is a private single family office providing principal investing services in Greater China healthcare and life sciences. The firm offers a single unified service focused on deploying proprietary family capital across four investment verticals: Biotech & Therapeutics, Medical Devices & MedTech, Digital Health & AI, and Healthcare Services & Infrastructure. The core service includes deal origination, due diligence, transaction structuring, position stewardship, risk governance, and exit planning capabilities.

Product and service5 records
1Principal Investing Services
CategoryCore service
2Biotech & Therapeutics Investment
CategoryInvestment vertical
3Medical Devices & MedTech Investment
CategoryInvestment vertical
4Digital Health & AI Investment
CategoryInvestment vertical
5Healthcare Services & Infrastructure Investment
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Chinese private equity firm with material healthcare and life sciences investment activity alongside other verticals. Comparable as a Greater China-focused principal investor with concentrated healthcare deal flow, though broader in sector mandate.

2CDB Capital
TypeRegional player
Description

China Development Bank's investment arm with significant healthcare and life sciences activity across Mainland China. Comparable as a Greater China healthcare investor, though institutionally distinct in origin, scale, and mandate.

TypeDirect peer
Description

Global healthcare-dedicated investment firm covering biotech, medical devices, and healthcare services across stages and geographies. Comparable as a sector-focused specialist investor with concentrated, conviction-driven healthcare exposure, though broader geographically.

TypeDirect peer
Description

Healthcare-focused investment firm with established Greater China presence investing across biotech, medical devices, and healthcare services. Comparable as a sector-specialist investor with concentrated conviction-driven approach to healthcare.

5CDH Investments
TypeBroad incumbent
Description

Established Greater China private equity firm with healthcare and life sciences investment activity. Comparable as a large-scale China-focused principal investor with cross-jurisdictional deal capabilities.

TypeBroad incumbent
Description

Major Greater China-focused private equity firm with healthcare exposure among its broad sector coverage. Comparable as a large-scale principal investor in Greater China, though much broader in sector mandate and substantially larger in AUM.

TypeDirect peer
Description

Healthcare-focused private equity firm with significant Greater China presence, investing across biotech, medical devices, and healthcare services. Comparable as a sector-specialist investor with concentrated healthcare focus across the same regional opportunity set.

TypeDirect peer
Description

Hong Kong-based healthcare-focused investment manager specializing in Greater China healthcare equities across biotech, medical devices, and healthcare services. Directly comparable as a healthcare-vertical specialist investor focused on the same regional opportunity set.

TypeDirect peer
Description

China-focused venture capital firm with one of the strongest healthcare and biotech portfolios in Greater China, investing across biotech, medical devices, and digital health. Comparable as a sector-active investor with concentrated healthcare exposure in the same geography.

TypeBroad incumbent
Description

One of the largest Asia-focused investment firms with significant healthcare and life sciences exposure across Greater China. Comparable as a major Greater China investor with healthcare vertical presence, though much broader in mandate and substantially larger in scale.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Rubix Group

Family Office Healthcare Investmentrubixgp.com

Rubix Group (HK) Limited is a Hong Kong-based private single family office that deploys proprietary family capital into Greater China healthcare and life sciences opportunities across biotech, medical devices, digital health, and healthcare services verticals, serving exclusively its controlling family group.

What Rubix Group does

Rubix Group (HK) Limited is a Hong Kong-incorporated private single family office, established in 2020, that deploys proprietary family capital into healthcare and life sciences opportunities across Greater China. The firm serves exclusively the members of its controlling family and family-owned investment holding vehicles; it does not solicit, accept, or manage capital from third parties and does not charge management or performance fees. Its sole 'customer' is the family itself, and its revenue, in the economic sense, is derived from investment gains on the family's own portfolio rather than from fee income.

The firm invests across four healthcare verticals in Greater China: Biotech & Therapeutics (novel biologics, small molecules, cell and gene therapy, oncology, immunology, CNS, rare disease, biosimilars); Medical Devices & MedTech (surgical robotics, diagnostic imaging, interventional devices, orthopaedics, IVD, wearables); Healthcare Services & Infrastructure (CRO/CDMO, hospital groups, specialty clinics, pharmacy chains, healthcare IT, laboratory services); and Digital Health & AI (AI drug discovery, telemedicine, clinical decision support, genomics, precision medicine) as an emerging focus. Its core capabilities cover deal origination through local biotech networks, independent commercial and scientific due diligence, bespoke transaction structuring (direct equity, convertibles, structured notes, SPVs), active position stewardship with board representation, risk governance, and exit planning across HKEX, Shanghai, and Shenzhen exchanges.

There is no proprietary technology platform; the firm's edge is grounded in on-the-ground presence in Hong Kong, local-language diligence, and relationships with Greater China healthcare management teams. Operating infrastructure is distributed across Hong Kong (principal entity), Cayman Islands (Rubix Capital SPC), British Virgin Islands (Rubix Capital (BVI) Ltd, an Approved Manager), and Malaysia (operations centre), while investment decision-making remains independent at Rubix Group (HK) Limited, which is not licensed by the Securities and Futures Commission of Hong Kong. The family principal, Alexander Ariana, serves as CEO and oversees the principal investing programme.

Rubix Group firmographics

Firmographics
Name
Rubix Group
Legal name
Rubix Group (HK) Limited
Website
https://rubixgp.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
Rubix Group (HK) Limited is a Hong Kong-based private single family office that deploys proprietary family capital into Greater China healthcare and life sciences opportunities across biotech, medical devices, digital health, and healthcare services verticals, serving exclusively its controlling family group.
Ownership category
akta.pro rank

Rubix Group industry classification

Industry
Product category
Family Office Healthcare Investment
NAICS
Portfolio Management and Investment Advice (523940)
SIC
Investors, Nec (6799)
akta.pro industry
PRIMARYFSAAADAH
Family Office Investment Platforms & Direct Investing (PE/VC/Co-Invest)
Financial & Insurance/Asset & Wealth Management/Family Offices (Single- & Multi-Family)

Keywords

  • Family office investing
  • Healthcare venture capital
  • Life sciences investment
  • Principal investing services
  • Private equity healthcare

Where Rubix Group is headquartered

Location

Headquarters

HQ city
Hong Kong
HQ country
Hong Kong SAR China
HQ region
Asia

Offices4 records

Markets served

Rubix Group business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Investment Returns on Proprietary Family Capital: Rubix Group generates returns through investment gains on the family's proprietary capital deployed across Greater China healthcare and life sciences opportunities. As a single family office, it does not charge management fees or performance fees to external clients. Revenue is derived entirely from appreciation and returns on the family's own investment portfolio.

Go-to-market motion1 record

Rubix Group product offering

Product offering

Core offering

Rubix Group is a Hong Kong-incorporated private single family office that deploys its controlling family's proprietary capital directly into Greater China healthcare and life sciences companies. The firm concentrates on four verticals — biotech and therapeutics, medical devices and MedTech, digital health and AI, and healthcare services and infrastructure — sourcing proprietary deal flow through local networks and managing direct equity, convertible, and structured positions as principal investor.

Product overview

Rubix Group is a private single family office providing principal investing services in Greater China healthcare and life sciences. The firm offers a single unified service focused on deploying proprietary family capital across four investment verticals: Biotech & Therapeutics, Medical Devices & MedTech, Digital Health & AI, and Healthcare Services & Infrastructure. The core service includes deal origination, due diligence, transaction structuring, position stewardship, risk governance, and exit planning capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

  • Principal Investing Services
  • Biotech & Therapeutics Investment
  • Medical Devices & MedTech Investment
  • Digital Health & AI Investment
  • Healthcare Services & Infrastructure Investment

Companies that use Rubix Group

Customer profile

Segments1 record

Ideal customer profiles1 record

Rubix Group technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Rubix Group partnerships and signals

Strategic signal

Recent moves5 records

Expansion highlights4 records

Rubix Group competitors and assessment

Company assessment

Direct peers

  • Loyal Valley Capital: Chinese private equity firm with material healthcare and life sciences investment activity alongside other verticals. Comparable as a Greater China-focused principal investor with concentrated healthcare deal flow, though broader in sector mandate.
  • OrbiMed: Global healthcare-dedicated investment firm covering biotech, medical devices, and healthcare services across stages and geographies. Comparable as a sector-focused specialist investor with concentrated, conviction-driven healthcare exposure, though broader geographically.
  • Vivo Capital: Healthcare-focused investment firm with established Greater China presence investing across biotech, medical devices, and healthcare services. Comparable as a sector-specialist investor with concentrated conviction-driven approach to healthcare.
  • Highlight Capital: Healthcare-focused private equity firm with significant Greater China presence, investing across biotech, medical devices, and healthcare services. Comparable as a sector-specialist investor with concentrated healthcare focus across the same regional opportunity set.
  • Lake Bleu Capital: Hong Kong-based healthcare-focused investment manager specializing in Greater China healthcare equities across biotech, medical devices, and healthcare services. Directly comparable as a healthcare-vertical specialist investor focused on the same regional opportunity set.
  • Qiming Venture Partners: China-focused venture capital firm with one of the strongest healthcare and biotech portfolios in Greater China, investing across biotech, medical devices, and digital health. Comparable as a sector-active investor with concentrated healthcare exposure in the same geography.

Regional players

  • CDB Capital: China Development Bank's investment arm with significant healthcare and life sciences activity across Mainland China. Comparable as a Greater China healthcare investor, though institutionally distinct in origin, scale, and mandate.

Broad incumbents

  • CDH Investments: Established Greater China private equity firm with healthcare and life sciences investment activity. Comparable as a large-scale China-focused principal investor with cross-jurisdictional deal capabilities.
  • Boyu Capital: Major Greater China-focused private equity firm with healthcare exposure among its broad sector coverage. Comparable as a large-scale principal investor in Greater China, though much broader in sector mandate and substantially larger in AUM.
  • Hillhouse Capital: One of the largest Asia-focused investment firms with significant healthcare and life sciences exposure across Greater China. Comparable as a major Greater China investor with healthcare vertical presence, though much broader in mandate and substantially larger in scale.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Rubix Group social profiles

Digital presence

Rubix Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Rubix Group leadership team

Management profile

Number of profiles

Profiles1 record

Rubix Group funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Rubix Group M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rubix Group

What does Rubix Group do?

Rubix Group is a Hong Kong-incorporated private single family office that deploys its controlling family's proprietary capital directly into Greater China healthcare and life sciences companies. The firm concentrates on four verticals — biotech and therapeutics, medical devices and MedTech, digital health and AI, and healthcare services and infrastructure — sourcing proprietary deal flow through local networks and managing direct equity, convertible, and structured positions as principal investor.

Is Rubix Group a public or private company?

Rubix Group is a private company. It is classified as family owned and is currently operating.

When was Rubix Group founded?

Rubix Group was founded in 2020. It employs 1 to 10 people.

Where is Rubix Group based?

Rubix Group is headquartered in Hong Kong, Hong Kong SAR China, in the Asia region.

How does Rubix Group make money?

One revenue line is on record: investment Returns on Proprietary Family Capital.

Who are Rubix Group's main competitors?

Direct peers on record are Loyal Valley Capital, OrbiMed, Vivo Capital, Highlight Capital, Lake Bleu Capital and Qiming Venture Partners. CDB Capital is listed as a regional player. Broad incumbents are CDH Investments, Boyu Capital and Hillhouse Capital.

Does Rubix Group have an API?

No public API is recorded for Rubix Group.

What industry is Rubix Group in?

Rubix Group's product category is Family Office Healthcare Investment. Its primary akta.pro industry code is FSAAADAH, Family Office Investment Platforms & Direct Investing (PE/VC/Co-Invest). Its NAICS code is 523940 and its SIC code is 6799.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales